Pharmacotherapy for adults with tumors of the central nervous system.
Tumors of the adult central nervous system are among the most common and most chemoresistant neoplasms. Malignant tumors of the brain and spinal cord collectively account for approximately 1.3% of all cancers and 2.2% of all cancer-related deaths. Novel pharmacological approaches to nervous system tumors are urgently needed. This review presents the current approaches and challenges to successful pharmacotherapy of adults with malignant tumors of the central nervous system and discusses novel approaches aimed at overcoming these challenges.
Schor
Nina F
NF
Departments of Pediatrics, Neurology, and Neurobiology & Anatomy, University of Rochester Medical Center, Rochester, NY, USA. nina_schor@urmc.rochester.edu
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005909:Glioblastoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D005910:Glioma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000473:pathology; D013120:Spinal Cord Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents